Eli Lilly and Company (NYSE:LLY) Shares Down 1.6% – Here’s Why

Posted by Geri Gentry on Oct 8th, 2026

Eli Lilly and Company logo Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) dropped 1.6% during trading on Thursday. The company traded as low as $1,131.21 and last traded at $1,169.7650. 3,074,844 shares were traded during mid-day trading, an increase of 3% from the average session volume of 2,974,658 shares. The stock had previously closed at $1,188.72.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Cantor Fitzgerald raised its price target to $1,440 and reiterated an “overweight” rating, implying substantial upside from recent levels. The call reflects confidence in Lilly’s earnings growth and pipeline. Cantor Fitzgerald price-target report
Positive Sentiment: Analysts and investors continue to highlight Lilly’s growth beyond Mounjaro and Zepbound. Retatrutide, a next-generation obesity candidate, has produced greater weight loss in trials and could be filed with regulators in early 2027. The broader obesity platform may also address fatty liver disease, sleep apnea and other conditions. Lilly obesity pipeline article
Positive Sentiment: New or expanding clinical studies for eloralintide, Alzheimer’s treatments and Lilly’s oncology portfolio provide additional long-term catalysts. Jaypirca, Inluriyo and Retevmo could help offset slower growth from mature products. Lilly pipeline update
Neutral Sentiment: Technical commentary identifies the 50-day moving average as an important support level and describes a move above it as a potential short-term bullish signal. However, technical support has not resolved the stock’s valuation concerns. Lilly moving-average analysis
Negative Sentiment: Investors remain concerned that Lilly trades at a premium multiple after its powerful GLP-1 rally. Competition, future pricing pressure and the long regulatory timeline for next-generation drugs could limit near-term upside.
Negative Sentiment: Early-stage trial announcements for eloralintide and Alzheimer’s therapies do not yet provide efficacy or approval evidence, so they offer limited immediate earnings support. The market is also awaiting further proof that pipeline products can sustain growth as current blockbusters mature.

Wall Street Analyst Weigh In

A number of research analysts recently commented on LLY shares. Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Truist Financial upped their price objective on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Guggenheim increased their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a report on Friday, August 7th. Finally, Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Check Out Our Latest Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Down 1.6%

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a 50 day simple moving average of $1,173.51 and a 200 day simple moving average of $1,094.59. The firm has a market capitalization of $1.10 trillion, a PE ratio of 39.25, a PEG ratio of 1.42 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the firm posted $6.31 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the stock. Coastal Bridge Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $2,959,000. Mosaic Family Wealth Partners LLC increased its stake in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after buying an additional 1,430 shares in the last quarter. Moran Wealth Management LLC increased its stake in Eli Lilly and Company by 85.6% in the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after buying an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC raised its holdings in Eli Lilly and Company by 17.5% during the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after acquiring an additional 1,521 shares during the period. Finally, Amundi lifted its position in shares of Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after acquiring an additional 454,549 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.